Cortechs.ai | Predicting MCI Outcome With Clinically Available MRI And CSF Biomarkers
Cortechs.ai | Predicting MCI Outcome With Clinically Available MRI And CSF Biomarkers
Contact
  • Home
  • /
  • Resources
  • /
  • Predicting MCI Outcome With Clinically Available MRI And CSF Biomarkers

Predicting MCI Outcome With Clinically Available MRI And CSF Biomarkers

  • Category: Published research

Study to determine the ability of clinically available volumetric MRI (vMRI) and CSF biomarkers, alone or in combination with a quantitative learning measure, to predict conversion to Alzheimer’s disease (AD) in patients with mild cognitive impairment (MCI). 2011 October 12.

[button]Download[/button]

  • Topic: Published research

More Resources

Cortechs.ai | Predicting MCI Outcome With Clinically Available MRI And CSF Biomarkers
  • 3 mins

09/03/2025

Reimbursement Considerations for OnQ Prostate and Category III CPT Codes 0648T & 0649T

Learn how Cat. III CPT codes 0648T and 0649T apply to OnQ™ Prostate, offering guidance for accurate reporting, reimbursement, and building evidence for coverage

Cortechs.ai | Predicting MCI Outcome With Clinically Available MRI And CSF Biomarkers
  • 2 mins

09/02/2025

Maximizing the Value of Prostate MRI for the Urologist

Even with expert radiologists or AI models at hand, the challenge remains: how can urologists improve seeing and interpreting cancer?

Cortechs.ai | Predicting MCI Outcome With Clinically Available MRI And CSF Biomarkers
  • 6 mins

08/18/2025

Why Bigger Normative Databases Mean Better Brain Imaging

NeuroQuant® 5.2 compares patient brain MRI volumes to over 7,000 healthy scans, giving clinicians clear, percentile-based context for better assessments.

Cortechs.ai | Predicting MCI Outcome With Clinically Available MRI And CSF Biomarkers
  • 5 mins

08/07/2025

Navigating Reimbursement for NeuroQuant: Understanding CPT Codes 0865T & 0866T 

Let’s break down the latest category III CPT codes and example clinical use cases that illustrate their value.

Cortechs.ai | Predicting MCI Outcome With Clinically Available MRI And CSF Biomarkers
  • 2 mins

07/31/2025

Precision Without the Pressure: Smarter Brain Tumor Monitoring

Learn about NeuroQuant Brain Tumor 2.0 and how it assists clinicians by providing objective quantification and analysis of tumor changes over time.

Cortechs.ai | Predicting MCI Outcome With Clinically Available MRI And CSF Biomarkers
  • 3 mins

07/30/2025

Cortechs.ai Announce Next-Gen NeuroQuant Brain Tumor: AI-Driven Metastasis & Meningioma Segmentation 

NeuroQuant Brain Tumor is the first FDA-cleared, cloud-native tool to offer automated volumetric segmentation for brain metastases, meningiomas, and gliomas.

View our insights
Cortechs.ai | Predicting MCI Outcome With Clinically Available MRI And CSF Biomarkers
Cortechs.ai | Predicting MCI Outcome With Clinically Available MRI And CSF Biomarkers

Empowering precision

and clarity in patient care

5060 Shoreham Place,
Ste 240, San Diego, CA 92122

Cortechs.ai | Predicting MCI Outcome With Clinically Available MRI And CSF Biomarkers
  • Solutions
  • © Cortechs.ai 2024
Scroll to Top